Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Last trade$27.67
Day change+$0.225 (+0.82%)
Day range$26.35 – $27.91
Volume1,453,816
Market cap$4.77B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.77B
Price / earnings
—
Price / book
9.25×
Price / sales
—
EV / sales
—
EV / EBITDA
-11.37×
Profitability
Earnings per share
-$2.11
Return on assets
-44.01%
Return on equity
-70.94%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.43×
Current ratio
10.99×
Quick ratio
10.99×
Cash ratio
2.97×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$325.78M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for COGT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$42.09M
$31.83M
$28.24M
$23.93M
$14.37M
$13.38M
$11.9M
$11.69M
Research and development
$75.1M
$70.81M
$75.37M
$75.56M
$68.99M
$62.2M
$63.03M
$62.05M
Total operating expenses
$117.18M
$102.64M
$103.61M
$99.49M
$83.36M
$75.58M
$74.93M
$73.73M
Operating income
-$117.18M
-$102.64M
-$103.61M
-$99.49M
-$83.36M
-$75.58M
-$74.93M
-$73.73M
Interest expense
-$1.24M
-$1.22M
-$1.21M
-$1.29M
-$1.46M
-$314K
$0
$0
Income before taxes
-$111.43M
-$96.41M
-$97.35M
-$102.49M
-$80.93M
-$73.53M
-$71.99M
-$67.93M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$111.43M
-$96.41M
-$97.35M
-$102.49M
-$80.93M
-$73.53M
-$71.99M
-$67.93M
Net income attributable to common shareholders
-$102.89M
-$88.93M
-$86.02M
-$88.42M
-$69.03M
-$60.88M
-$59.47M
-$55.58M
EBITDA
-$116.61M
-$101.9M
-$102.98M
-$98.87M
-$82.71M
-$74.93M
-$74.29M
-$73.11M
Basic earnings per share
-$0.59
-$0.52
-$0.53
-$0.59
-$0.50
-$0.53
-$0.52
-$0.50
Diluted earnings per share
-$0.59
-$0.52
-$0.53
-$0.59
-$0.50
-$0.53
-$0.52
-$0.50
Recent news
Company coverage with links to the original publishers.
Healthcare sector is experiencing a significant rebound, with ETFs hovering near 52-week highs driven by double-digit earnings growth expectations, positive clinical trial results, attractive valuations, and expanding GLP-1 adoption. Major pharmaceutical companies reported promising drug-trial outcomes in oncology, obesity, and rare diseases, while M&A activity surged to nearly $284 billion. The sector is benefiting from a rotation out of overcrowded AI/tech trades into defensive growth.
Cogent Biosciences announced preclinical data presentations at the 2026 AACR Annual Meeting for two pipeline programs: CGT1263, a pan-KRAS(ON) inhibitor showing >500x selectivity over HRAS/NRAS with potential to reduce skin toxicity, and CGT4255, a brain-penetrant ErbB2 inhibitor demonstrating synergistic activity with HER2 ADCs. The company expects to submit an IND for CGT1263 later in 2026 and continues Phase 1 studies for CGT4255.
RTW Investments made a significant $116 million purchase of Cogent Biosciences shares in Q4, increasing its stake to 2.7% of AUM. The move signals confidence in the biotech company's lead drug candidate (CGT9486) and upcoming FDA decision timeline in late 2026. Cogent's stock has surged 360% over the past year, and the company has $900 million in cash runway through 2028.
Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.
Cogent Biosciences stock surged 5.24% after the FDA accepted its New Drug Application for bezuclastinib, a treatment for Non-Advanced Systemic Mastocytosis. The FDA decision is expected by December 30, 2026, with no advisory committee meeting planned. The company also plans to submit additional NDAs for GIST and Advanced Systemic Mastocytosis treatments in 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.